drugset / Trial / NCT02400281
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open label, two-arm, Phase I-II trial, non-randomized. Arm 1: crenolanib with standard chemotherapy (Idarubicin/Cytarabine, MEC;Mitoxantrone/Etoposide/Cytarabine, FLAG-Ida: Fludarabine/Cytarabine/G-CSF/Idarubicin) Arm 2: crenolanib with 5-azacitidine
Timeline
- Start
- 2015-09
- Primary completion
- 2020-07-15
- Completion
- 2020-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Crenolanib | Small molecule | — | — |
| Background | Azacytidine | Other / unclassified | — | — |
| Background | Cytarabine | Small molecule | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | G-CSF | Unknown | — | — |
| Background | Idarubicin | Small molecule | — | — |
| Background | Mitoxantrone | Small molecule | — | — |